GLP-1 Medications and Female Fertility: What the Research Shows

*This article is for informational and educational purposes only. It is not medical advice. Compounded semaglutide and tirzepatide are not FDA-approved medications. The clinical research cited here was conducted using FDA-approved branded formulations. Results from studies of FDA-approved medications may not apply to compounded products. Individual results vary. Consult your licensed healthcare provider, reproductive endocrinologist, and pharmacist before starting, stopping, or adjusting any medication. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or employ physicians.*

---

One in six couples in the United States struggles to conceive. For women with obesity or polycystic ovary syndrome (PCOS), the path to pregnancy is often harder still. Excess weight disrupts the hormonal signals that govern ovulation, and PCOS is the single most common cause of anovulatory infertility in reproductive-age women. The two conditions frequently overlap, compounding their effects on fertility.

GLP-1 receptor agonists, the class of medications that includes semaglutide and tirzepatide, have attracted enormous attention for their effects on weight and metabolic health. More recently, a growing body of research has examined whether these medications also affect fertility. The findings are genuinely interesting and are generating serious discussion in reproductive medicine circles. They also come with important limitations and safety considerations that anyone thinking about this topic needs to understand.

This article documents what the current evidence shows, what it does not yet prove, and what it means practically for women navigating the intersection of metabolic health and reproductive goals.

---

How Obesity Disrupts Female Reproductive Function

Understanding why researchers are looking at GLP-1 medications in the fertility context starts with understanding what excess weight does to the reproductive system.

Insulin resistance and androgen excess. Obesity promotes insulin resistance, a state where cells respond less efficiently to insulin. The pancreas compensates by producing more insulin. In the ovaries, elevated insulin levels stimulate excess production of androgens (male sex hormones including testosterone). This androgen surplus interferes with normal follicle development and disrupts the hormonal feedback loop that governs ovulation.

Disrupted ovulation. In women with obesity, ovulatory dysfunction is common even without a formal PCOS diagnosis. Cycles become irregular or absent. When ovulation does not occur reliably, conceiving naturally becomes significantly harder. Some women do not realize their cycles have been affected until they start trying to conceive.

Egg quality and endometrial receptivity. Research suggests that the metabolic abnormalities associated with obesity, particularly elevated insulin and chronic low-grade inflammation, can affect oocyte (egg) quality and reduce endometrial receptivity, the uterine lining's capacity to accept a fertilized egg. Even when conception occurs, the risk of early pregnancy loss is higher in women with obesity.

A 2026 review in Obesity Reviews concluded that obesity-related insulin resistance is a primary driver of reproductive dysfunction in premenopausal women, and that metabolic interventions addressing insulin resistance hold significant theoretical promise for improving reproductive outcomes (PMID 41077659).

---

PCOS: The Metabolic-Reproductive Overlap

PCOS affects approximately 1 in 10 women of reproductive age and accounts for roughly 80 percent of anovulatory infertility cases. Despite being the most common reproductive endocrine disorder, it is frequently undertreated or identified late.

At its core, PCOS is a metabolic condition with reproductive consequences. Insulin resistance drives androgen excess, which suppresses normal ovulatory signaling. The pituitary gland releases disproportionate amounts of luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH), disrupting the cycle of follicle maturation that leads to ovulation. The result is irregular or absent periods, elevated testosterone, and often, difficulty conceiving.

Weight loss, achieved by any effective and sustained means, is associated with improved ovulatory function in women with PCOS. The central question researchers have been investigating is whether GLP-1 medications, through their effects on weight and insulin sensitivity, can restore ovulatory regularity in a clinically meaningful way.

A 2025 systematic review published in Therapeutic Advances in Endocrinology and Metabolism analyzed data from multiple clinical trials and observational studies, finding that GLP-1 receptor agonists reduced androgen levels, improved menstrual regularity, and in some studies restored ovulation in PCOS patients with obesity (PMID 41069706). The authors identified insulin resistance reduction as the primary mechanism driving these reproductive benefits, rather than weight loss acting through a separate pathway.

---

What the Research Shows

Semaglutide, PCOS, and Restored Ovulation

A 2026 pilot prospective study published in Clinical Nutrition ESPEN enrolled women with PCOS and obesity and treated them with a combination of semaglutide and metformin over 24 weeks. Researchers tracked weight changes, insulin resistance markers, androgen levels, and menstrual cycle regularity. At the end of the study period, a significant proportion of participants who had previously had irregular cycles showed improved regularity. Free androgen levels declined in parallel with weight loss (PMID 41421448). The study was small and open-label, meaning both participants and researchers knew who was receiving treatment. Larger placebo-controlled trials are needed. But the findings are consistent with the mechanistic picture that has been building across other research.

The Evidence Map for Incretin Medications in PCOS

A 2026 evidence review published in Drugs specifically mapped the available clinical data on GLP-1 receptor agonists and PCOS outcomes across studies dating from the earliest liraglutide trials through the current semaglutide era. The review found consistent evidence for improvements in menstrual regularity, testosterone levels, and metabolic markers, with the quality of evidence strongest for liraglutide and a growing body of data for semaglutide (PMID 42106472). The authors identified several ongoing randomized controlled trials that are expected to provide higher-quality evidence over the next few years.

A 2026 Narrative Review

A comprehensive 2026 narrative review in the Journal of Clinical Medicine synthesized available evidence on GLP-1 receptor agonists, fertility restoration, and reproductive safety across multiple outcomes, including ovulatory function, IVF performance, and pregnancy safety data (PMID 42122936). The review found biologically plausible and, in multiple studies, clinically measurable effects on reproductive endpoints. It also underscored a significant gap: fertility has not been tracked as a primary outcome in the large weight management trials that established GLP-1 medications as effective for obesity treatment. The evidence base is growing rapidly, but it is still primarily coming from smaller studies and secondary analyses.

---

IVF and Assisted Reproductive Technology

For women pursuing in vitro fertilization (IVF) or other assisted reproductive technologies, the relationship between body weight and success rates is well-documented. Women with obesity tend to have lower clinical pregnancy rates, reduced response to ovarian stimulation medications, and higher miscarriage rates per IVF cycle compared to women at healthy weights. These differences are not trivial. They can mean significantly more cycles to achieve a successful pregnancy, substantially higher costs, and more emotional strain.

Whether GLP-1-facilitated weight loss before IVF can improve outcomes is an active area of research. A 2025 review in Obstetrics and Gynecology by Finkle and colleagues examined the role of GLP-1 receptor agonists in people with infertility, noting that pre-conception weight reduction achieved through these medications may improve the metabolic conditions necessary for successful reproduction in women with obesity-related infertility (PMID 39847778). The review also flagged the importance of stopping GLP-1 medications well in advance of conception attempts.

A 2026 clinical perspectives review in the European Journal of Contraception and Reproductive Health Care examined timing protocols, safety considerations, and the available IVF outcome data, concluding that GLP-1 receptor agonists have a plausible role in pre-conception metabolic preparation but that prospective randomized trials are needed before formal clinical guidance can be established (PMID 41860479).

---

Critical Safety Consideration: Stopping Before Conception

This section contains the most important practical information in this article.

GLP-1 medications should not be used during pregnancy. Animal reproductive toxicology studies have shown adverse developmental outcomes at high doses. These medications carry warnings about use during pregnancy, and the current medical consensus is clear: stop GLP-1 medications before attempting to conceive.

The standard guidance in reproductive medicine is to discontinue GLP-1 receptor agonists at least two months before trying to conceive. For weekly injectable formulations of semaglutide and tirzepatide, the drug's half-life means several weeks of clearance time after the last dose. A two-month window provides a conservative safety margin.

This timing has direct practical implications for anyone considering GLP-1 medications as part of a pre-conception weight management strategy. The approach would be to use the treatment period to achieve meaningful metabolic improvement and weight loss, then stop the medication and stabilize with lifestyle changes before beginning conception attempts.

Contraception during treatment is essential. Some women taking GLP-1 medications for metabolic reasons do not realize that improved ovulatory function, as a result of the hormonal changes these medications produce, can restore fertility in women who had previously been anovulatory. Restored ovulation can occur without prior notice or regular cycling. Women who are sexually active and not planning an immediate pregnancy should use reliable contraception throughout their treatment. This is not hypothetical: unintended pregnancies in women who did not realize their ovulatory status had changed have been documented in the medical literature.

Oral contraceptive absorption. GLP-1 medications slow gastric emptying, which may affect the absorption of oral medications including birth control pills. Women taking both should speak with their provider about contraceptive reliability and whether alternative forms of contraception are preferable during GLP-1 treatment.

---

What This Means in Practice

GLP-1 medications are not fertility treatments. They are approved for weight management and, in certain formulations, for type 2 diabetes. Prescribing them specifically to treat infertility is off-label use, not supported by current clinical guidelines, and not something any provider should recommend without careful individual evaluation.

What the research does show is mechanistically coherent. These medications reduce insulin resistance and produce substantial, sustained weight loss. Both of those effects appear to improve the hormonal environment of the reproductive system in women with PCOS and obesity. Improved menstrual regularity and ovulation restoration are reported across multiple studies, even though large randomized controlled trials with fertility as the primary endpoint do not yet exist.

For women trying to understand their options before pursuing fertility treatment, this research is worth knowing. It positions metabolic health as a meaningful component of reproductive health, not a separate concern. Weight is not simply a cosmetic issue in this context; it is part of the physiological system that governs fertility.

Decisions about using GLP-1 medications in any fertility-related context should involve both a prescribing provider and, ideally, a reproductive endocrinologist. These specialties are increasingly communicating about exactly these questions as the evidence continues to develop.

---

Summary

• Obesity disrupts female fertility through insulin resistance, androgen excess, and ovulatory dysfunction.
• PCOS affects roughly 1 in 10 reproductive-age women and is the leading cause of anovulatory infertility.
• Multiple 2025-2026 studies show GLP-1 receptor agonists can reduce androgens and improve menstrual regularity in women with PCOS and obesity.
• A pilot study found improved ovulatory function and hormonal markers with semaglutide combined with metformin over 24 weeks.
• GLP-1 medications are not approved as fertility treatments; the evidence is promising but early.
• These medications must be stopped before attempting conception. Most guidance recommends at least two months of clearance.
• Restored ovulation in previously anovulatory women can occur unexpectedly during treatment; reliable contraception is essential.

Ready to explore your options? A licensed provider can help you understand whether medically supervised weight management makes sense for your goals.

[Check your eligibility for Prescriva's weight management program.](/quiz)

---

*Compounded medications are not FDA-approved. This program is not a fertility treatment. Results vary by individual. All clinical decisions are made by licensed providers based on individual medical evaluation. Blue Oak Services LLC dba Prescriva is a management services organization providing technology and administrative services only.*

---

Sources

1. Abedi MM et al. "GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review." *J Clin Med.* 2026 Apr 22. PMID: 42122936

1. Jensterle M et al. "Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map." *Drugs.* 2026 May 9. PMID: 42106472

1. Dilbaz B et al. "The effects of glucagon-like peptide-1 receptor agonists on fertility, contraception, and pregnancy: clinical perspectives." *Eur J Contracept Reprod Health Care.* 2026 Mar 20. PMID: 41860479

1. Hoteit BH et al. "The dual impact of GLP-1 receptor agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials." *Ther Adv Endocrinol Metab.* 2025. PMID: 41069706

1. Finkle J et al. "Role of Glucagon-Like Peptide-1 Receptor Agonists in People With Infertility and Pregnancy." *Obstet Gynecol.* 2025 Mar 1. PMID: 39847778

1. Roberts R et al. "Obesity and Female Reproductive Health; Is There a Role for Glucagon-Like Peptide-1 Receptor Agonists?" *Obes Rev.* 2026 Feb. PMID: 41077659

1. Bolek T et al. "Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study." *Clin Nutr ESPEN.* 2026 Feb. PMID: 41421448